47 results about "Pericardial effusion" patented technology

A fluid management system for the treatment of ascites, pleural effusion or pericardial effusion is provided including an implantable device including a pump, control circuitry, battery and transceiver; a charging and communication system configured to periodically charge the battery and communicate with the implantable device to retrieve performance data; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable device and charging and communication system. The implantable device includes a number of features that provide automated movement of fluid to the bladder with reduced risk of clogging, with no patient involvement other than occasional recharging of the battery of the implantable device. The monitoring and control software is available only to the treating physician, such that the physician interacts with the implantable device via the charging and communication system.

A system for noninvasively monitoring cancerous cells within bodily fluid accumulated due to ascites, pleural effusion or pericardial effusion is provided including an implantable pump having control circuitry; a charging and communication system configured to periodically charge and communicate with the implantable pump to retrieve performance data; and monitoring and control software, suitable for use with conventional personal computers, for configuring and controlling operation of the implantable pump and charging and communication system. The implantable pump is configured to move fluid containing cancerous cells from a body cavity to the bladder such that the fluid may be excreted during urination, collected and analyzed with an analysis station to assess progress of the cancer or efficacy of a cancer treatment program.

A fluid management system for moving bodily fluid accumulated due to ascites, pleural effusion or pericardial effusion is provided including an implantable pump coupled to an inflow catheter, an outflow catheter, and optionally an anti-clog catheter. The fluid management system facilitates removal of fluid from a body region, such as the peritoneum, pleural cavity or pericardial sac, where drainage is desired to another body region, such as the urinary bladder or the peritoneal cavity. The system includes clog resistant mechanisms such as clog resistant catheters and/or programmed routines for cycling fluid through inlet catheters in predetermined time intervals and/or responsive to sensed conditions to minimize the risk that inlet catheters become clogged due to, for example, tissue ingrowth and/or solid objects within accumulated fluid.

The invention discloses a group I type 4 aviadenovirus strain WZ. The strain has a preservation number of China Center for Type Culture Collection (CCTCC) No: V201662, is named as group I type 4 aviadenovirus strain WZ in a classified way, and is preserved in December 14, 2016; a group I type 4 viral vaccine of the aviadenovirus is prepared from the inactivated group I type 4 aviadenovirus strain which is taken as an active ingredient; the invention also provides application of the group I type 4 aviadenovirus strain WZ in preparation of an agar gel precipitating antigen, a hemagglutination inhibition (HI) antigen and positive serum antigen reagent which are used for diagnosing the group I type 4 virus of the aviadenovirus, and preparation of egg yolk antibody and antiserum which are used for treating the group I type 4 virus of the aviadenovirus. After the vaccine prepared by using the group I type 4 aviadenovirus strain is used for immunizing, the toxin attacking protection rate for the group I type 4 aviadenovirus strain WZ reaches 90-100%. As a vaccine strain with good manufacturing effect, the group I type 4 aviadenovirus strain WZ can be used for preventing avian inclusion body hepatitis and pericardial effusion syndrome, and also can be used for virus identification and epidemiological investigation.

A method of using fluid aspirates as vehicles for drug delivery by collecting a fluid aspirate such as synovial joint effusion, pleural effusion, pericardial effusion, or ascites from a patient and centrifuging the fluid aspirate to provide a supernatant and a sedimented material. The sedimented material can optionally be further purified. One or more factors such as cytokines, bone morphogenetic proteins (BMPs), pharmaceutical drugs and gene vectors are added to the sedimented material or supernatant, optionally also including a biologically compatible medium such as a bioabsorbable sponge, so as to provide a vehicle for the one or more factors for reintroducion into the patient.

The invention provides a triad trocar device for deep tissue puncture. The triad trocar device comprises a thick puncture needle, a puncture cannula and a fine puncture needle; in the puncture process, when shallow tissue is punctured, the tips of the thick puncture needle, the puncture cannula and the fine puncture needle are aligned; when deep tissue is punctured, the puncture cannula and the fine puncture needle extend out of the first end of the thick puncture needle and pierce into the deep tissue together, then the fine puncture needle is withdrawn, and a channel is established between the deep tissue and the exterior of the body of a subject through the puncture cannula. By means of the puncturing device and method, important tissue organ damage can be reduced when the deep tissue is punctured, the sensitivity of the deep tissue during puncturing is increased, and the success rate of puncturing is improved, so that clinical prognosis is improved, and the device and method can beapplied to clinical practice such as pericardial effusion puncture drainage and subclavicular vein puncture catheterization, and have high clinical application value.

The invention relates to the technical field of a biological veterinary drug, in particular to a preparation method of a biological veterinary drug for preventing and treating hydropericardium hepatitis syndrome in chickens. The preparation method comprises steps of preparing an antigen, determining an antigen EID50, preparing an inactivated vaccine, immunizing laying chickens, collecting eggs from hype-immunized chickens and extracting an anti-hydropericardium hepatitis syndrome egg yolk antibody. According to the egg yolk antibody biological veterinary drug for treating the hydropericardium hepatitis syndrome in chickens provided by the invention, chicken embryo proliferating viruses are inoculated to liver tissue homogenate of chickens affected by the hydropericardium hepatitis syndrome in chickens, the laying chickens are immunized by the prepared inactivated vaccine, protein is extracted from egg yolks and the protein is used for preventing and treating the hydropericardium hepatitis syndrome in chickens, so as to solve the problem that a targeted veterinary drug for treating the hydropericardium hepatitis syndrome in chickens is in lack at present and the problems that a current popular treatment scheme is high in cost and poor in effect.

The invention belongs to the technical field of disease prevention of agricultural breeding, and particularly relates to application of taxol in prevention and treatment of pericardial effusion of chickens. The taxol is used for a feed additive for preventing and treating the pericardial effusion of the chickens. Compared with the prior art, the application of taxol in prevention and treatment of pericardial effusion of chickens has the advantages that new application of the taxol is provided, and the taxol is used for preventing and treating the pericardial effusion of the chickens, and plays an important role in large-scale breeding of broilers; and the taxol, evening primrose oil and tylosin are used in feedstuff in a matched manner, and the pericardial effusion of the chickens can be effectively prevented and treated in a growth stage of the chickens, meanwhile, immunity of the organism can further be improved, and high feed conversion ratio and high production performance can be kept.

The invention relates to the technical field of veterinary biological products, in particular to a group I avian adenovirus type 8 strain and application thereof. The group I avian adenovirus type 8 strain ZMYTAV-8 strain, with an accession number of CGMCC No. 14297 has the characteristics of high toxin production and good immunogenicity. The strain can effectively prevent chicken inclusion body hepatitis caused by serum avian adenovirus type 8. Therefore, the invention also provides application of the avian adenovirus type 8 strain ZMYTAV-8 in the preparation of drugs for the prevention of inclusion body hepatitis. Further, the present invention provides a bivalent inactivated vaccine of avian adenovirus serotype 4, serotype 8 for the prevention of pericardial effusion-hepatitis syndromeand inclusion body hepatitis. The vaccine has good immunogenicity and can prevent avian diseases caused by adenovirus, such as inclusion body hepatitis and pericardial effusion-hepatitis syndrome, which are popular in recent years. The vaccine has 100% protection rate against local isolates, and has high safety, rapid antibody production and stable efficacy.

The invention provides a traditional Chinese medicine composition for preventing and treating the hydropericardium-hepatitis syndrome of poultry. The traditional Chinese medicine composition is prepared from, by weight, 10-20 parts of cassia twigs, 20-30 parts of cattail pollen, 15-25 parts of rhizoma curcumae longae, 15-25 parts of peach kernels, 10-30 parts of radix paeoniae rubra, 10-30 parts of rhizoma alismatis, 10-30 parts of radix curcumae, 10-25 parts of fructus aurantii immaturus and 10-30 parts of rhizoma atractylodis macrocephalae. The invention further provides a preparation method and application of the traditional Chinese medicine composition for preventing and treating the hydropericardium-hepatitis syndrome. The traditional Chinese medicine composition has the effects of warming yang and dispelling qi stagnation, invigorating the spleen to remove dampness, promoting blood circulation to remove blood stasis, and harmonizing the five internal organs, and can effectively treat the hydropericardium-hepatitis syndrome of poultry in clinical application.

The invention discloses a universal thoracic retention drainage tube, which comprises a double-chamber duct with flexibility and plasticity, wherein one chamber is a washing chamber, the other chamber is a drainage chamber, and the section of the washing chamber is smaller than the section of the drainage chamber; the front end of the double-chamber duct is processed into a circle shaped leading-in part, while the rear end is provided with a washing horn mouth communicated with the washing chamber and a drainage horn mouth communicated with the drainage chamber; and the inner side of the circle of the leading-in part is provided with a drainage hole communicated with the drainage chamber, while the outer side is provided with a washing hole communicated with the washing chamber. The universal thoracic retention drainage tube is provided with the drainage chamber and the washing chamber simultaneously and can simultaneously perform drainage and washing; the drainage chamber is large and not easy to block, so the drainage is more complete; a bending head design avoids damaging viscera and reduces irritant indisposition; and the universal thoracic retention drainage tube has wide application range, is suitable for treating pleural effusion, pericardial effusion and pyothorax, has low cost and can repeatedly wash and drain after once posting.

The invention provides methods for rapid isolation of microorganisms from positive culture sterile body fluids, including blood, cerebrospinal fluid (CSF), pleural fluid, ascitic fluid, pericardial effusion, joint cavity fluid, vitreous fluid, and amniotic fluid for mass spectrometry identification. Whenever the subject of blood culture is discussed, the intended sample used is always related to blood sample. However, it is also necessary to be aware that other than the blood sample, sterile fluids can also be inoculated as samples for blood culture testing. Among the sterile fluids that are commonly known are CSF, pleural fluid, ascitic fluid, pericardial effusion, joint cavity fluid, vitreous fluid, amniotic fluid etc. The methods involve combining micro-volume positive blood culture sample with detergent solution to lyse human blood cells, then isolating the microorganism by differential centrifugation process that first removes interfering substances such as charcoal (when present), resins and human blood cellular debris through a low speed centrifugation, then isolates the microorganisms in the sample supernatant through a fast centrifugation. The methods not only apply to regular blood culture media but also apply to antimicrobial removal containing media such as resin containing BD BACTEC™ Plus-Aerobic media and charcoal-containing Biomerieux BacT/Alert® FA media. In addition, the methods can isolate a variety of Gram-positive bacteria, Gram-negative bacteria, and yeast in clinical settings. The isolated microorganism(s) from positive blood culture can be used for multiple downstream analyses, including identification of the microorganism(s) by mass spectrometry, phonotypical, or molecular identification methods.

The present invention relates to the technical field of medical auxiliary devices and particularly relates to a pericardial effusion auxiliary drainage device. The pericardial effusion auxiliary drainage device comprises a puncture needle and a liquid storage tank, an upper part of an outer side wall of the puncture needle is provided with a connecting handle, besides, a needle body of the puncture needle is provided with a liquid inlet inner chamber and a liquid outlet inner chamber, a top end port of the liquid inlet inner chamber communicates with a liquid inlet connection pipe and a top end port of the liquid outlet inner chamber port communicates with a liquid outlet connection pipe; the other end of the liquid inlet connection pipe communicates with a liquid inlet pipeline, the otherend of the liquid outlet connection pipe communicates with a Y-shaped pipeline, the other ends of the Y-shaped pipeline respectively communicate with a liquid guiding pipe and an air guiding pipe, and inner chambers of the Y-shaped pipeline and liquid guiding pipe are respectively provided with a one-way valve; and the other end of the liquid guiding pipe communicates with a connecting pipe of the liquid storage tank, and besides, the other end of the air guiding pipe communicates with a suction cylinder. The pericardial effusion auxiliary drainage device is simple in structure and simple inoperation, can input physiological saline into pericardia of patients through the device after effusion is extracted from the patients, and has strong practicability and extremely excellent market promotion value.

The invention relates to the technical field of cardiology department nursing, and discloses a pericardial effusion constant-pressure drainage device for cardiology department nursing. The device comprises a drainage device main body, an isolation layer is fixedly arranged inside the drainage device main body, an air bag is fixedly arranged inside the drainage device main body, a heating chamber is fixedly arranged inside the air bag, and the bottom of the air bag is fixedly connected with an air guide pipe. Air in the air bag is heated through the heating chamber in the air bag, the air is continuously heated and can leave through the air guide pipe at the top of the air bag, a sliding rod in the air guide pipe can be jacked to vertically move upwards along with rising of the air, a valveblock in a valve groove vertically moves upwards to enable the air guide pipe to communicate, air voids are generated inside the air bag to attract air at the bottom of the isolation layer, negativepressure is generated at the bottom of the isolation layer, pericardial effusion is continuously attracted through a drainage tube, and the effect of maintaining the drainage device main body to generate stable negative pressure is achieved.

The invention belongs to the field of micro-organic zooblast system. The invention adopts pericardial effusion of human lung adenocarcinoma patients as a material for building the system and establishes a parental human lung adenocarcinoma cell line with high potential of bone metastasis through cell cultivation, which is called CPA-Y1; and the preservation number of the parental human lung adenocarcinoma cell line is CGMCC No.2521. The established cell line can provide reference data for carrying out early diagnose on human lung adenocarcinoma bone metastases; relevant gene chip technology can be further established; and treatment effect of various medicaments comprising chemical medicaments, biological medicaments, immune medicaments, Chinese medicaments, radioactive medicaments and the like can be evaluated and researched. The parental human lung adenocarcinoma cell line provides a technological platform for searching and diagnosing human lung adenocarcinoma bone metastases and systematically studying multiple lung cancer metastasis. Meanwhile, the parental human lung adenocarcinoma cell line can be used for further analyzing functional genome related to lung cancer bone metastasis and genes related to bone metastasis to provide an effective molecular detection method for early diagnosis and evaluation of treatment effect of bone metastasis.

The invention relates to the technical field of medical instruments, in particular to a pericardial effusion extraction device for the emergency department. The pericardial effusion extraction device comprises a base, a positioning mechanism and a suction mechanism; a shell is rotatably arranged on the upper end surface of the base, a shell inner cavity is limited in the shell, and a fixed inner plate is fixedly arranged on a center line of the bottom surface of the shell inner cavity in the front-back direction; the positioning mechanism comprises a rotating outer shaft rotationally arranged on the position, close to the upper portion, of the front end face of the base; and the suction mechanism comprises a first fixed cylinder fixedly connected to the upper end surface of the fixed inner plate. The problems that in the pericardial effusion extraction process, a puncture needle is not fixed, stability is poor, the replacing time of an extraction tube is long in the effusion extraction process, and consequently, the life safety of a patient is affected are solved.

The invention belongs to the technical field of cardiology treatment, and in particular relates to a traditional Chinese medicine composition for recovering pericardial effusion and a preparation method thereof. Wherein the medicine for internal use is composed of the following components by mass: 4-6 parts of Hedyotis diffusa, 3-5 parts of Scutellaria barbata, 3-5 parts of Hedyotis diffusa, 3-5 parts of Cuiyucao, 6-6 parts of soybean 8 parts, 4‑6 parts star anise, 4‑6 parts Andrographis paniculata, 3‑5 parts hydra, 3‑5 parts purslane, 1‑2 parts Arthrophyllum, 4‑6 parts Burnet, Gynostemma 3 ‑5 parts, 4‑6 parts of Atractylodes Rhizome, 3‑5 parts of Baishouwu, 3‑5 parts of keel; the medicine for external use is composed of the following components in parts by mass: 4‑6 parts of Rhizoma Imperatae, 4‑6 parts of Radix Isatidis, 3-5 parts of Jincao, 3-5 parts of Venus Grass, 4-6 parts of Moutan Bark, 3-5 parts of Menthol, 4-6 parts of Erigeron breviscapus, 4-6 parts of Thyme, 5-8 parts of Angelica, 5 parts of Magnolia officinalis ‑8 servings. The invention uses oral Chinese medicinal preparations to astringe wounds to promote wound healing, and at the same time utilizes externally applied medicines to introduce therapeutic medicinal liquids to promote disease recovery and achieve good curative effect.